Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Intra-host evolution provides for continuous emergence of SARS-CoV-2 variants

Justin T. Landis, Razia Moorad, Linda J. Pluta, Carolina Caro-Vegas, Ryan P McNamara, Anthony B. Eason, Aubrey Bailey, Femi Cleola S. Villamor, Angelica Juarez, Jason P. Wong, Brian Yang, Grant S. Broussard, Blossom Damania, View ORCID ProfileDirk P. Dittmer
doi: https://doi.org/10.1101/2021.05.08.21256775
Justin T. Landis
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Razia Moorad
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda J. Pluta
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Caro-Vegas
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan P McNamara
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony B. Eason
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aubrey Bailey
2Kuopio Center for Gene and Cell Therapy, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Femi Cleola S. Villamor
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelica Juarez
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason P. Wong
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Yang
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grant S. Broussard
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Blossom Damania
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk P. Dittmer
1Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dirk P. Dittmer
  • For correspondence: ddittmer@med.unc.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Variants of concern (VOC) in SARS-CoV-2 refer to viral genomes that differ significantly from the ancestor virus and that show the potential for higher transmissibility and/or worse clinical progression. VOC have the potential to disrupt ongoing public health measures and vaccine efforts. Yet, little is known regarding how frequently different viral variants emerge and under what circumstances. We report a longitudinal study to determine the degree of SARS-CoV-2 sequence evolution in 94 COVID-19 cases and to estimate the frequency at which highly diverse variants emerge. 2 cases accumulated ≥9 single-nucleotide variants (SNVs) over a two-week period and 1 case accumulated 23 SNVs over a three-week period, including three non-synonymous mutations in the Spike protein (D138H, E554D, D614G). We estimate that in 2% of COVID cases, viral variants with multiple mutations, including in the Spike glycoprotein, can become the dominant strains in as little as one month of persistent in patient virus replication. This suggests the continued local emergence of VOC independent of travel patterns. Surveillance by sequencing for (i) viremic COVID-19 patients, (ii) patients suspected of re-infection, and (iii) patients with diminished immune function may offer broad public health benefits.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NA

Funding Statement

This work was supported by funding from the Medical Foundation of North Carolina, the NC Collaboratory, and public health service grants 5UM1CA121947-10 to R.P.M, 2P01CA01901438 to J.D.G, and B.D., and 2-R01-DE018304-10, 1-R01-CA239583-01 to D.P.D. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Sample use was approved under human subjects approvals # 20-2448 and # 13-2140 by the Institutional Review Board (IRB) at the University of North Carolina; CB 7097, 720 Martin Luther King Jr. Blvd. Bldg # 385, Second Floor, Chapel Hill, NC 27599-7097.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Full-length SARS-CoV-2 genomes that met the confidence and quality criteria detailed below were uploaded to GISAID. Other sequences, including index cases, were obtained through GISAID.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 10, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Intra-host evolution provides for continuous emergence of SARS-CoV-2 variants
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Intra-host evolution provides for continuous emergence of SARS-CoV-2 variants
Justin T. Landis, Razia Moorad, Linda J. Pluta, Carolina Caro-Vegas, Ryan P McNamara, Anthony B. Eason, Aubrey Bailey, Femi Cleola S. Villamor, Angelica Juarez, Jason P. Wong, Brian Yang, Grant S. Broussard, Blossom Damania, Dirk P. Dittmer
medRxiv 2021.05.08.21256775; doi: https://doi.org/10.1101/2021.05.08.21256775
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Intra-host evolution provides for continuous emergence of SARS-CoV-2 variants
Justin T. Landis, Razia Moorad, Linda J. Pluta, Carolina Caro-Vegas, Ryan P McNamara, Anthony B. Eason, Aubrey Bailey, Femi Cleola S. Villamor, Angelica Juarez, Jason P. Wong, Brian Yang, Grant S. Broussard, Blossom Damania, Dirk P. Dittmer
medRxiv 2021.05.08.21256775; doi: https://doi.org/10.1101/2021.05.08.21256775

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1746)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (651)
  • Epidemiology (10771)
  • Forensic Medicine (8)
  • Gastroenterology (582)
  • Genetic and Genomic Medicine (2930)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1917)
  • Health Policy (832)
  • Health Systems and Quality Improvement (741)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12495)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (319)
  • Neurology (2778)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (553)
  • Occupational and Environmental Health (596)
  • Oncology (1452)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (254)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (378)
  • Pediatrics (863)
  • Pharmacology and Therapeutics (361)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2626)
  • Public and Global Health (5336)
  • Radiology and Imaging (1001)
  • Rehabilitation Medicine and Physical Therapy (592)
  • Respiratory Medicine (721)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (124)